Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
27 Mars 2023 - 2:00PM
Business Wire
- California’s Desert Oasis Healthcare (DOHC) implements Rimidi’s
Respiratory Module for respiratory patient monitoring, based on
data collected by Teva’s Digihaler® System
- Digihaler is the first and only smart inhaler system that can
provide objective data to help patients and their doctors better
support asthma management
- Teva and Rimidi look to expand respiratory monitoring program
to additional health systems with the aim of assessing potential
cost savings, hospitalization rates and the quality of asthma
management
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA), today announced that a
respiratory patient monitoring program using data from Teva’s
Digihaler System has been implemented within California’s Desert
Oasis Healthcare (DOHC) system. The program was designed in
collaboration with Rimidi, a leading clinical management platform
designed to optimize clinical workflows, enhance patient
experiences and achieve quality objectives. Teva’s Digihaler is the
first and only smart inhaler system that can provide objective data
to help patients and their doctors better support asthma
management.
The implementation of this respiratory monitoring program in a
large health system is a vital step in helping to ensure patients
are getting the resources they need to develop informed treatment
plans with their doctors. Teva and Rimidi continue to look for ways
to expand this respiratory monitoring program by partnering with
additional health systems in an effort to reduce high costs, lower
hospitalizations and improve asthma management.
“Teva aims to be a leader in fusing technology and healthcare in
order to help patients and their doctors more easily manage their
treatment plans. Through collaborations with partners like Rimidi,
we hope to improve the patient continuum of care, leading to a more
cost-effective healthcare system,” said Manny Montalvo, Senior Vice
President, Head of Digital Health & Innovation at Teva. “More
than 34 million Americans live with a chronic lung disease, and
approximately 25 million people in the U.S. currently have asthma.1
We’re energized by the potential of collaborations like this to
drive meaningful differences in how asthma is managed and treated,
with the collective vision of one day predicting asthma attacks
before they occur.”
Through this collaboration, DOHC has identified patients with
respiratory conditions indicated for treatment with one or more of
the products in Teva’s Digihaler family of inhalers, and who are
appropriate candidates for enrollment via the Rimidi platform. Data
from Teva’s Digihaler System will be available through Rimidi’s
Respiratory Module, which is designed to give providers a more
complete view of the patient to help guide treatment decisions for
those with respiratory diseases, such as chronic obstructive
pulmonary disease (COPD) or asthma.
“The ability to have a streamlined, comprehensive view of a
patient’s health condition allows for more efficient and
personalized management,” said Lucienne Ide, MD, PhD, Founder and
CEO of Rimidi. “Rimidi’s Respiratory Module incorporates clinical
decision support tools to help clinicians understand potential
reasons behind a patient’s uncontrolled asthma, such as not taking
their medication or not taking it properly. These factors are
fundamental to achieving good asthma control.”
Integrating data from the smart inhalers into the clinician’s
electronic health records through the Respiratory Module can help
support the management of COPD and asthma. Longer term, outcomes
from DOHC’s initial patient cohort will provide valuable insights
to inform the use of data from Teva’s Digihaler System and the
module in U.S. health systems. The platform can be used to monitor
and manage large populations by a network of health systems,
capturing objective and actionable data for asthma patients. The
goal is to assess how this approach can help address high costs,
lower hospitalizations and improve asthma management.
About Teva Teva Pharmaceutical Industries Ltd.
(NYSE and TASE: TEVA) has been developing and producing medicines
to improve people’s lives for more than a century. We are a global
leader in generic and innovative medicines with a portfolio
consisting of over 3,500 products in nearly every therapeutic area.
Around 200 million people around the world take a Teva medicine
every day, and are served by one of the largest and most complex
supply chains in the pharmaceutical industry. Along with our
established presence in generics, we have significant innovative
research and operations supporting our growing portfolio of
innovative and biopharmaceutical products. Learn more at
www.tevapharm.com.
About Teva Digital Health Teva aims to be a global
leader in personalized, predictive care, continuously investing in
platforms and regulatory-compliant systems that will help change
the nature of digital health as we know it. Teva’s proprietary
software platform, Digihaler® – developed and maintained in-house
by a team of research specialists and programmers – is built into a
series of FDA-approved inhalers, currently marketed in the U.S.
Learn more at www.Digihaler.com.
About Rimidi Created by doctors, Rimidi’s leading
clinical management platform empowers healthcare organizations to
optimize clinical workflows, enhance patient experiences and
achieve quality objectives. By bringing together clinical decision
support, remote patient monitoring and patient reported outcomes in
a unified, composable, FHIR-based platform, Rimidi supports a broad
range of clinical use cases and institutional priorities across
large and small healthcare organizations. For more information,
visit rimidi.com and follow us on Twitter and LinkedIn.
About Desert Oasis Healthcare Formed in 1981 as one
of the first medical groups in the desert communities of southern
California, Desert Oasis Healthcare (DOHC) continues to advance
with changes in the healthcare market. DOHC provides primary and
immediate care, home health, palliative care, and other services to
more than 60,000 members/patients living in the greater Coachella
Valley and the Morongo Basin of Riverside and San Bernardino
counties. The multidisciplinary and comprehensive care programs of
DOHC are committed to educating individuals on preventative health
care in their daily lives, reflected in the DOHC motto, "Your
Health. Your Life. Our Passion." For more information, visit
http://www.mydohc.com.
Cautionary Note Regarding Forward-Looking
Statements This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, which are based on management’s current beliefs
and expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to the development and
commercial success of our Digihaler products family; our ability to
successfully compete in the marketplace, including our ability to
develop and commercialize biopharmaceutical products, competition
for our innovative medicines, including AUSTEDO®, AJOVY® and
COPAXONE®, our ability to achieve expected results from investments
in our product pipeline, our ability to develop and commercialize
additional pharmaceutical products, and the effectiveness of our
patents and other measures to protect our intellectual property
rights; our substantial indebtedness; our business and operations
in general, including, the impact of global economic conditions and
other macroeconomic developments and the governmental and societal
responses thereto, and costs and delays resulting from the
extensive pharmaceutical regulation to which we are subject;
compliance, regulatory and litigation matters, including failure to
comply with complex legal and regulatory environments; other
financial and economic risks; and other factors discussed in our
Annual Report on Form 10-K for the year ended December 31, 2022,
including in the section captioned “Risk Factors.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
statements.
- The American Lunch Association. Our Impact (2023).
https://www.lung.org/about-us/our-impact.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230327005150/en/
IR Contacts United States Ran Meir (267) 468-4475
Sanjeev Sharma (973) 524-1908 PR Contacts United
States Kelley Dougherty (973) 658-0237 Yonatan Beker (973)
264-7378
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024